Specific expression of osteopontin and S100A6 in hepatocellular carcinoma

Surgery

Volumn 149, Issue 6, 2011, Pages 783-791

  Hua, Zhan ^a   Chen, Jingzhou ^b   Sun, Baishun ^a   Zhao, Gonghua ^a   Zhang, Yuanchun ^a   Fong, Yuman ^c   Jia, Zhengeng ^a   Yao, Li ^a  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b FUWAI HOSPITAL   (China)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCYCLIN; COMPLEMENTARY DNA; OSTEOPONTIN;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CLONE; CONTROLLED STUDY; CYTOSKELETON; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; STAINING;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; OSTEOPONTIN; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; S100 PROTEINS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79957694795     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2010.12.007     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2002;2005(55):74-108.
2. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999;353:1253-7. (Pubitemid 29168472)
3. Yang BH, Xia JL, Huang LW, Tang ZY, Chen MS, Li JQ, et al. [Changes of clinical aspect of primary liver cancer in China during the past 30 years - control study for 3,250 cases with primary liver cancer]. Zhonghua Yi Xue Za Zhi 2003;83:1053-7.
4. Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002;235:533-9. (Pubitemid 34258353)
5. Sun HC, Tang ZY. Preventive treatments for recurrence after curative resection of hepatocellular carcinoma - a literature review of randomized control trials. World J Gastroenterol 2003;9:635-40.
6. Thorgeirsson SS. Hunting for tumor suppressor genes in liver cancer. Hepatology 2003;37:739-41.
7. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002;21:2593-604. (Pubitemid 34438112)
8. Xu XR, Huang J, Xu ZG, Qian BZ, Zhu ZD, Yan Q, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci U S A 2001;98:15089-94. (Pubitemid 34013974)
9. Xiao SY, Wang HL, Hart J, Fleming D, Beard MR. cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma. Am J Pathol 2001;159:1415-21. (Pubitemid 32947971)
10. Cheung ST, Chen X, Guan XY, Wong SY, Tai LS, Ng IO, et al. Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Res 2002;62:4711-21.
11. Hoshida Y,MoriyamaM,OtsukaM,KatoN,GotoT,TaniguchiH, et al. Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells. J Gastroenterol 2002; 37(Suppl 14):92-5.
12. ChumaM, SakamotoM, Yamazaki K,Ohta T,OhkiM, Asaka M, et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 2003;37:198-207. (Pubitemid 36042161)
13. Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, Mori N, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003;361:923-9. (Pubitemid 36332108)
14. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416-23. (Pubitemid 36460075)
15. Wilentz RE, Su GH, Dai JL, Sparks AB, Argani P, Sohn TA, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 2000;156:37-43. (Pubitemid 30644436)
16. Tiniakos DG, Yu H, Liapis H. Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP). Hum Pathol 1998;29:1250-4. (Pubitemid 28525525)
17. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 1999;5:2271-7. (Pubitemid 29399287)
18. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio- Donahue C, Rahman A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:487-91. (Pubitemid 38737477)
19. Irby RB, McCarthy SM, Yeatman TJ. Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis 2004;21:515-23.
20. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003;98:119-27.
21. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 2002;52:19-24. (Pubitemid 34299209)
22. Xie H, Song J, Du R, Liu K, Wang J, Tang H, et al. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis 2007;39:167-72. (Pubitemid 46117934)
23. HeizmannCW, Fritz G, SchaferBW. S100 proteins: structure, functions and pathology. Front Biosci 2002;7:d1356-68.
24. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 2006;396:201-14. (Pubitemid 43837235)
25. Emberley ED, Murphy LC, Watson PH. S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol 2004;82:508-15. (Pubitemid 39286966)
26. Yang YQ, Zhang LJ, Dong H, Jiang CL, Zhu ZG, Wu JX, et al. Upregulated expression of S100A6 in human gastric cancer. J Dig Dis 2007;8:186-93.
27. Ito Y, Yoshida H, Tomoda C, Uruno T, Miya A, Kobayashi K, et al. Expression of S100A2 and S100A6 in thyroid carcinomas. Histopathology 2005;46:569-75. (Pubitemid 40632314)
28. Ohuchida K, Mizumoto K, Ishikawa N, Fujii K, Konomi H, Nagai E, et al. The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin Cancer Res 2005;11:7785-93. (Pubitemid 41611622)
29. Komatsu K, Andoh A, Ishiguro S, Suzuki N, Hunai H, Kobune- Fujiwara Y, et al. Increased expression of S100A6 (Calcyclin), a calcium-binding protein of the S100 family, in human colorectal adenocarcinomas. Clin Cancer Res 2000;6:172-7. (Pubitemid 30064991)
30. Maelandsmo GM, Florenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O. Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer 1997;74:464-9. (Pubitemid 27400171)
31. Komatsu K, Kobune-Fujiwara Y, Andoh A, Ishiguro S, Hunai H, Suzuki N, et al. Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma. Br J Cancer 2000;83:769-74.
32. Breen EC, Tang K. Calcyclin (S100A6) regulates pulmonary fibroblast proliferation, morphology, and cytoskeletal organization in vitro. J Cell Biochem 2003;88:848-54. (Pubitemid 36258834)
33. Nedjadi T, Smith R, Jenkins RE, Costello E. Involvement of S100A6 (CALCYCLIN) in pancreatic progression. Pancreas 2007;35:419.
34. Whiteman HJ, Weeks ME, Dowen SE, Barry S, Timms JF, Lemoine NR, et al. The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D. Cancer Res 2007;67:8633-42. (Pubitemid 47437439)
35. Chambers AF, Hota C, Prince CW. Adhesion of metastatic, ras-transformed NIH 3T3 cells to osteopontin, fibronectin, and laminin. Cancer Res 1993;53:701-6.
36. Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen JY. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 2007;67:2089-97.
37. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem 2004;279:38921-35. (Pubitemid 39296053)
38. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 2003;278:28593-606. (Pubitemid 36935765)
39. Christensen B, Kazanecki CC, Petersen TE, Rittling SR, Denhardt DT, Sorensen ES. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem 2007;282:19463-72. (Pubitemid 47100061)
40. Hsieh YH, Juliana MM, Hicks PH, Feng G, Elmets C, Liaw L, et al. Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin. Cancer Res 2006;66:7119-27. (Pubitemid 44197689)
41. Cook AC, Chambers AF, Turley EA, Tuck AB. Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy. J Biol Chem 2006;281:24381-9. (Pubitemid 44274210)